









Markets
/
Stocks
/
nasdaq-vnda
/

Vanda Pharmaceuticals Inc

VNDA

4.520USD

+0.130+2.96%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

267.04MMarket Cap

LossP/E TTM



Vanda Pharmaceuticals Inc

4.520

+0.130+2.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

75 / 507

Overall Ranking

186 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.667

Target Price

+184.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 18.90M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -3.85, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 50.75M shares, decreasing 18.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.54M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.75, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 52.59M, representing a year-over-year increase of 4.19%, while its net profit experienced a year-over-year increase of 502.19%.

Score

Industry at a Glance

Previous score

7.75

Change



Financials

6.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.29

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.85, which is -698.94% below the recent high of 23.05 and -271.21% above the recent low of -14.29.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Vanda Pharmaceuticals Inc is 13.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.667

Target Price

+188.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Vanda Pharmaceuticals Inc

VNDA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.17, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 4.75 and the support level at 4.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

-0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Sell

RSI(14)

49.276

Neutral

STOCH(KDJ)(9,3,3)

33.944

Buy

ATR(14)

0.152

High Vlolatility

CCI(14)

-59.366

Neutral

Williams %R

71.429

Sell

TRIX(12,20)

-0.025

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.452

Buy

MA10

4.501

Buy

MA20

4.583

Sell

MA50

4.565

Sell

MA100

4.515

Buy

MA200

4.566

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 85.90%, representing a quarter-over-quarter increase of 4.28%. The largest institutional shareholder is The Vanguard, holding a total of 3.54M shares, representing 5.99% of shares outstanding, with 0.31% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.02M

+0.28%

The Vanguard Group, Inc.

Star Investors

3.50M

-0.31%

Renaissance Technologies LLC

Star Investors

3.57M

-7.46%

Millennium Management LLC

3.12M

+45.84%

Dimensional Fund Advisors, L.P.

2.54M

+2.06%

BlackRock Financial Management, Inc.

2.15M

+0.70%

Tang Capital Management, LLC

2.35M

Polymeropoulos (Mihael Hristos)

2.33M

+1.31%

Acadian Asset Management LLC

1.89M

-0.68%

Geode Capital Management, L.L.C.

1.61M

+11.26%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.39, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.73. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.